Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NEOTORCH-BREAST03: Anlotinib + Benmelstobart in HR+/HER2- Breast Cancer
NCT06874933Phase 2Recruiting
- Sponsor
- First Affiliated Hospital, Zhejiang University School of Medicine
- Start
- May 2025
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label trial of anlotinib and benmelstobart in breast cancer (2 arms), sponsored by First Affiliated Hospital, Zhejiang University School of Medicine. Primary endpoints: Pathologic Complete Response at 2 years and Residual Cancer Burden 0-1 Ratio at 2 years. Started May 2025; status: recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT06874933.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06874933.